Compass Therapeutics, Inc. filed its quarterly report on Form 10-Q with the SEC on August 6, 2026, covering the period ended June 30, 2026, disclosing operating expenses, cash position, and balance sheet figures for the first half of the year.

Key Highlights

  • Net loss of $25.154 million for the three months ended June 30, 2026, compared to a net loss of $19.881 million in the same period of 2025, according to the filing.
  • Total operating expenses of $26.979 million for Q2 2026, consisting of $19.576 million in research and development and $7.403 million in general and administrative expenses.
  • Cash and cash equivalents of $35.453 million and marketable securities of $144.426 million as of June 30, 2026, per the balance sheet.
  • Total assets of $190.173 million as of June 30, 2026, down from $219.588 million at December 31, 2025.
  • 180,088,000 shares of common stock issued and outstanding as of June 30, 2026, with 180,087,915 shares reported outstanding as of July 28, 2026.
  • Net cash used in operating activities was $32.007 million for the six months ended June 30, 2026, versus $25.040 million in the comparable prior-year period.

Compass Therapeutics' Operating and Balance Sheet Activity Through June 2026

Compass Therapeutics, Inc. (Nasdaq Capital Market: CMPX), a Delaware-incorporated biopharmaceutical company headquartered in Boston, Massachusetts, reported a net loss of $43.471 million for the six months ended June 30, 2026, compared to a net loss of $36.514 million for the same period in 2025, according to the filing. Total operating expenses for the first half of 2026 reached $47.278 million, comprised of $32.968 million in research and development costs and $14.310 million in general and administrative expenses. The company recorded interest income of $3.807 million for the six-month period, compared to $2.518 million in the first half of 2025.

On the balance sheet as of June 30, 2026, the filing disclosed total stockholders' equity of $166.049 million, down from $196.791 million at December 31, 2025. The accumulated deficit stood at $474.643 million at quarter-end, compared to $431.172 million at year-end 2025. Additional paid-in-capital increased to $640.925 million from $627.665 million, reflecting $9.895 million in share-based compensation and $3.854 million in proceeds from the exercise of common stock options during the six-month period, as disclosed in the statements of cash flows and stockholders' equity.

The company reported net cash provided by investing activities of $33.452 million for the first half of 2026, driven by $119.140 million in proceeds from the sale or maturities of marketable securities, partially offset by $85.430 million in purchases of marketable securities and $258,000 in property and equipment purchases. The filing states cash, cash equivalents, and restricted cash totaled $36.021 million at June 30, 2026, compared to $31.211 million at the start of the period.

What Was Disclosed

Compass Therapeutics filed its Form 10-Q for the quarter ended June 30, 2026, reporting a net loss of $25.154 million for Q2 2026, total assets of $190.173 million, and total stockholders' equity of $166.049 million, with 180,088,000 shares of common stock outstanding at quarter-end.